Prophylactic antibiotics for preventing early Gram-positive central venous catheter infections in oncology patients, a Cochrane systematic review.
OBJECTIVE
Long-term tunnelled central venous catheters (TCVC) are increasingly used in oncology patients. Infections are a frequent complication of TCVC, mostly caused by Gram-positive bacteria. The objective of this review is to evaluate the efficacy of antibiotics in the prevention of early Gram-positive TCVC infections, in oncology patients.


METHODS
We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Register up to July 2003.


METHODS
We selected randomised controlled trials (RCT) evaluating prophylactic antibiotics prior to insertion of the TCVC, and the combination of an antibiotic and heparin to flush the TCVC, in paediatric and adult oncology patients. The primary outcome was documented Gram-positive bacteraemia in patients with a TCVC. All trials identified were assessed and the data extracted independently by two reviewers.


RESULTS
There were nine trials included. Four trials reported on vancomycin/teicoplanin prior to insertion of the TCVC compared to no antibiotics. There was no reduction in the number of Gram-positive TCVC infections with an Odds ratio of 0.42 (95% confidence interval 0.13-1.31). Five trials studied flushing of the TCVC with a vancomycin/heparin solution compared to heparin flushing only. This method decreased the number of TCVC infections significantly with an Odds ratio of 0.43 (95% CI 0.21-0.87).


CONCLUSIONS
Flushing the TCVC with a vancomycin/heparin solution reduced the incidence of Gram-positive infections.
van de Wetering
M D
MD
Paediatric Oncology Department, Emma Children's Hospital/Academic Medical Centre, F8-245, Meibergdreef 9, 1105 AD Amsterdam, The Netherlands. m.d.vandewetering@amc.uva.nl
van Woensel
J B M
JB
Kremer
L C M
LC
Caron
H N
HN
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D019072:Antibiotic Prophylaxis / Q000379:methods*; D000925:Anticoagulants / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D016908:Gram-Positive Bacterial Infections / Q000209:etiology / Q000517:prevention & control*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D017334:Teicoplanin / Q000008:administration & dosage; D014640:Vancomycin / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D000925:Anticoagulants; D000970:Antineoplastic Agents; D017334:Teicoplanin; D014640:Vancomycin; D006493:Heparin